Hodgkin Lymphoma SurvivorNCT02106611
Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) Survivors
An observational study of Hodgkin Lymphoma Survivor, run by Memorial Sloan Kettering Cancer Center at 1 site in United States.
Trial summary
This study will test whether cardiac MRI can improve early detection of Hodgkin lymphoma associated heart disease compared to a stress echocardiogram. By doing both stress echocardiography and cardiac MRI, we will compare the ability of the two tests to detect heart disease. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hodgkin Lymphoma Survivor
- What is being tested?
- Clinical Assessment, Stress cardiac MRI and Stress echocardiogram
- Type of treatment
- Surgery or procedure
- How many people
- 133 participants
- Where
- 1 siteUnited States
- Study dates
- Apr 2014to 6 Feb 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: MSKCC
Who may be able to join
- Classical or nodular lymphocyte predominant HL treated at Memorial Sloan-Kettering Cancer Center.
- Age ≥ 18 years
- Treatment for HL that included mediastinal RT at initial diagnosis or relapse.
- ≥ 5 years from last HL treatment.
Who cannot join
- Primary HL diagnosis prior to 1980.
- Additional mediastinal RT or subsequent cardiotoxic systemic therapy for secondary malignant neoplasm.
- Known CAD/CHF (defined as documented myocardial infarction, cardiac revascularization, angiographic obstructive CAD, or decreased LV function [EF < 55%] during prior clinical care).
- Contraindication to MRI (i.e. pacemakers, defibrillators, or aneurysm clips, or other implanted ferromagnetic objects), gadolinium (i.e. known hypersensitivity to gadolinium, advanced renal insufficiency as defined by glomerular filtration rate <30 ml/min/1.73m^2).
- Contraindication to exercise stress testing other than the above (i.e. unstable angina or severe valvular stenosis).
Trial locations and contacts
1 site in 1 country.
United States1 site
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
About this study
This study will test whether cardiac MRI can improve early detection of Hodgkin lymphoma associated heart disease compared to a stress echocardiogram. By doing both stress echocardiography and cardiac MRI, we will compare the ability of the two tests to detect heart disease.
- Conditions
- Hodgkin Lymphoma Survivor
- Being tested
- Clinical Assessment, Stress cardiac MRI, Stress echocardiogram
- Keywords
- MRI, stress echo, Clinical Assessment, 14-017
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Clinical AssessmentOther
HL treatment will be determined by review of available medical records as archived at MSKCC. Recorded variables will include: (1) RT - field, fractional and cumulative dose, and duration; (2) chemotherapy - regimen, planned interval, dose per cycle, and cumulative dosages. Patients will also be asked to complete the FACT-LYM questionnaire and the FACIT Fatigue questionnaire.
Stress cardiac MRIProcedure or surgery
Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
Stress echocardiogramProcedure or surgery
Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
| Study group | Role | What they receive |
|---|---|---|
| Hodgkin Lymphoma Survivor | This is a prospective cross-sectional study of 200 HL survivors whose treatment included mediastinal RT at initial diagnosis or relapse, and are at least 5 years from last HL treatment. Receives: Other: Clinical Assessment; Procedure: Stress cardiac MRI; Procedure: Stress echocardiogram |
What is being measured
The primary outcome is the main question the study is designed to answer.
compare the prevalence of cardiac injury
detected by cardiac MRI to that detected by stress echocardiography among a broadly representative cohort of Hodgkin lymphoma survivors.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Apr 2014 (estimated)
- Study startApr 2014
- Primary completion6 Feb 2026
- Study completion6 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hodgkin Lymphoma SurvivorStudies of the same condition, open and under way.
- More trials run by Memorial Sloan Kettering Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 133 participants (actual)
Sponsor and investigators
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- Weill Medical College of Cornell University
- Responsible party
- Sponsor
- Investigators
- Alison Moskowitz, MD, Principal investigator, Memorial Sloan Kettering Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02106611
- Sponsor's protocol ID
- 14-017
- Status last verified
- Feb 2026
- First submitted
- 3 Apr 2014
- Last updated
- 11 Feb 2026
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) Survivors
- ClinicalTrials.gov ID
- NCT02106611
- Acronym / sponsor ID
- 14-017
- Conditions
- Hodgkin Lymphoma Survivor
- Keywords
- MRI, stress echo, Clinical Assessment, 14-017
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 133 participants (actual)
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterUniversity, hospital or other
- Collaborators
- Weill Medical College of Cornell University
- Study start
- Apr 2014 (actual)
- Primary completion
- 6 Feb 2026 (actual)
- Study completion
- 6 Feb 2026 (actual)
- First posted
- 8 Apr 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will test whether cardiac MRI can improve early detection of Hodgkin lymphoma associated heart disease compared to a stress echocardiogram. By doing both stress echocardiography and cardiac MRI, we will compare the ability of the two tests to detect heart disease.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Hodgkin Lymphoma Survivor | – | Other: Clinical Assessment, Procedure: Stress cardiac MRI, Procedure: Stress echocardiogramThis is a prospective cross-sectional study of 200 HL survivors whose treatment included mediastinal RT at initial diagnosis or relapse, and are at least 5 years from last HL treatment. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- MSKCC
Key inclusion criteria (4 listed)
- Classical or nodular lymphocyte predominant HL treated at Memorial Sloan-Kettering Cancer Center.
- Age ≥ 18 years
- Treatment for HL that included mediastinal RT at initial diagnosis or relapse.
- ≥ 5 years from last HL treatment.
Key exclusion criteria (5 listed)
- Primary HL diagnosis prior to 1980.
- Additional mediastinal RT or subsequent cardiotoxic systemic therapy for secondary malignant neoplasm.
- Known CAD/CHF (defined as documented myocardial infarction, cardiac revascularization, angiographic obstructive CAD, or decreased LV function [EF < 55%] during prior clinical care).
- Contraindication to MRI (i.e. pacemakers, defibrillators, or aneurysm clips, or other implanted ferromagnetic objects), gadolinium (i.e. known hypersensitivity to gadolinium, advanced renal insufficiency as defined by glomerular filtration rate <30 ml/min/1.73m^2).
- Contraindication to exercise stress testing other than the above (i.e. unstable angina or severe valvular stenosis).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Clinical AssessmentHL treatment will be determined by review of available medical records as archived at MSKCC. Recorded variables will include: (1) RT - field, fractional and cumulative dose, and duration; (2) chemotherapy - regimen, planned interval, dose per cycle, and cumulative dosages. Patients will also be asked to complete the FACT-LYM questionnaire and the FACIT Fatigue questionnaire. | Other | Hodgkin Lymphoma Survivor |
| Stress cardiac MRIBoth imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality. | Procedure or surgery | Hodgkin Lymphoma Survivor |
| Stress echocardiogramBoth imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality. | Procedure or surgery | Hodgkin Lymphoma Survivor |
Primary outcome
compare the prevalence of cardiac injury
Time frame: 2 years
detected by cardiac MRI to that detected by stress echocardiography among a broadly representative cohort of Hodgkin lymphoma survivors.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Feb 2026.
- Memorial Sloan Kettering Cancer CenterLink provided by the sponsor.
Related trials for Hodgkin Lymphoma Survivor
Active, not recruitingObservational study
Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Active, not recruitingObservational study
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Acute Lymphoblastic Leukemia, Hodgkin Lymphoma
Recruiting
Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors
Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
Active, not recruiting
A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In Greece
Blood Cancers, Leukemia
RecruitingObservational study
Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors
Hodgkin Lymphoma, Adult
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alison Moskowitz, MD principal investigator
Memorial Sloan Kettering Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hodgkin Lymphoma Survivor, run by Memorial Sloan Kettering Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
compare the prevalence of cardiac injury (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Feb 2026.